| LDR | | 00000nmm u2200205 4500 |
| 001 | | 000000332228 |
| 005 | | 20241127144619 |
| 008 | | 181129s2018 ||| | | | eng d |
| 020 | |
▼a 9780438033764 |
| 035 | |
▼a (MiAaPQ)AAI10750842 |
| 035 | |
▼a (MiAaPQ)unc:17542 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
| 049 | 1 |
▼f DP |
| 082 | 0 |
▼a 615 |
| 100 | 1 |
▼a Wan, Xiaomeng. |
| 245 | 10 |
▼a Poly(2-Oxazoline) Micellar Formulation For Cancer Therapy. |
| 260 | |
▼a [S.l.] :
▼b The University of North Carolina at Chapel Hill.,
▼c 2018 |
| 260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2018 |
| 300 | |
▼a 217 p. |
| 500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B. |
| 500 | |
▼a Adviser: Alexander V. Kabanov. |
| 502 | 1 |
▼a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018. |
| 520 | |
▼a Most nanoparticles have a fairly low threshold for incorporation of such drugs. Previously, we have reported a nanosized polymeric micelles (PM) formulation based on highly defined amphiphilic triblock copolymers of poly(2-oxazoline)s (POx), pol |
| 520 | |
▼a The co-delivery of drugs in a single nanofomulation remains a principal challenge since poor solubility and differential pharmacokinetics (PK) severely restricts the selection of drugs that can be translated into successful combination treatment |
| 590 | |
▼a School code: 0153. |
| 650 | 4 |
▼a Pharmaceutical sciences. |
| 690 | |
▼a 0572 |
| 710 | 20 |
▼a The University of North Carolina at Chapel Hill.
▼b Pharmaceutical Sciences. |
| 773 | 0 |
▼t Dissertation Abstracts International
▼g 79-10B(E). |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0153 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2018 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T14997135
▼n KERIS |
| 980 | |
▼a 201812
▼f 2019 |
| 990 | |
▼a 관리자
▼b 관리자 |